Connect your AI

Annexon ANNX Operating Lease ROU Assets

Operating Lease ROU Assets at other companies

Dianthus TherapeuticsDNTH

$1.29M-10.6%

OmerosOMER

$9.52M-31.8%

Vor BiopharmaVOR

$2.83M-91.6%

Cullinan Therapeutics, Inc.CGEM

$2.44M+57.2%

AnaptysBio, Inc.ANAB

$12.04M-13.5%

Amylyx Pharmaceuticals, Inc.AMLX

$4.88M+289%

Segments

By geography

Brisbane California$14.8M-9.2%

Other financials

Income statement

Operating income-$46.1M+19.8%

Net income-$44.1M+18.8%

EPS (diluted)-$0.23+37.8%

Balance sheet

Cash & equivalents$175.2M+80.4%

Total debt$25.4M-10.2%

Total equity$204.5M-16.1%

Total assets$262.9M-13.2%

Cash flow

Operating cash flow-$46.8M+6.5%

CapEx--100%

Free cash flow-$46.8M+6.6%

Valuation

Market cap$868.37M+223%

Enterprise value$718.59M+261%

Returns & leverage

Return on equity-87.6%+42.3pp

Debt / equity0.1×0.0×

Current ratio6.4×-1.6×

Where this comes from

Reported directly by Annexon in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAsset.

The official record: Annexon’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Annexon's operating lease rou assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Annexon's operating lease ROU assets?: Annexon (ANNX) reported operating lease ROU assets of $14.77M in Q1 2026.
How has Annexon's operating lease ROU assets changed year-over-year?: Annexon's operating lease ROU assets decreased by 9.7% year-over-year, from $16.35M to $14.77M.
What is the long-term trend for Annexon's operating lease ROU assets?: Over 4 years (2021 to 2025), Annexon's operating lease ROU assets has grown at a -7.0% compound annual growth rate (CAGR), from $20.33M to $15.19M.
What does operating lease ROU assets mean?: Right-of-use assets representing the lessee's right to use leased property over the lease term under ASC 842 operating lease classification.